HealthDay on MSN2h
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
GLP-1 RA use tied to lower rate of venous thromboembolism in diabetes
For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
Medscape2d
Dipeptidyl Peptidase-4 Inhibitors: Clinical Data and Clinical Implications
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation ... the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...
Hosted on MSN2d
SGLT-2 Inhibitors Beneficial for Patients With Nephrolithiasis
A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...
Daily1d
SGLT2 inhibitors linked to lower glaucoma risk, reveals research
A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to ...
Too Old to Operate3d
Lower Risk of Glaucoma with SGLT2i Treatment in Adults with Diabetes
The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...
Daily3d
Sitagliptin Improves Glycemic Control and Protect Kidneys in Adolescents with Type 1 Diabetes, New Study Finds
Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...
ahajournals.org4d
Abstract 4134298: Dipeptidyl Peptidase 4 Promotes Pressure Overload-Induced Heart Failure through enhancing Antigen Presentation
Background: Antigen presentation to CD4+ T cells plays a critical role in heart failure (HF). Dipeptidyl peptidase 4 (DPP4) has been shown to promote the activation of T lymphocytes. This study aims ...
Medscape4d
The Time Is Right for a New Classification System for Diabetes
β-cell–Centric Construct: A Potential Model for the Classification of DM Given the above discussion, the issue is not "what is LADA" or any clinical presentation of DM under the current system.
Nature3d
Fresh from the biologic pipeline—2009
It can thus be argued that, 'spiritually' at least, the interleukin-6 (IL-6) inhibitor Actemra (tocilizumab) belongs to the class of 2009. The drug, developed by Genentech, of S. San Francisco ...
Frontiers5d
Ramadan fasting and exercise combination therapy: A novel approach for osteoporosis prevention in ovariectomized rats
Background: Osteoporosis is a chronic bone metabolic disease that affects millions of people worldwide, particularly the elderly and postmenopausal women. It is characterized by weakened bones, ...